trial

The Norwegian Prednisolone in Early Psychosis Study

NCTId NCT03340909
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Terminated
Enrollment 12 (actual)
Sponsored by Haukeland University Hospital
Primary completion 2021-12-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Terminated
Enrollment
12 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2018-02-02
Primary completion
2021-12-31
Eligibility
ALL · 18 Years · 70 Years

Interventions & indications

Drugs
Prednisolone

Sponsors

Haukeland University HospitalLead Sponsor
Helse Stavanger HFCollaborator
St. Olavs HospitalCollaborator

Investigators

3
Erik Johnsen, MD, PhDPrincipal Investigator
Solveig Klæbo Reitan, MD, PhDPrincipal Investigator
Helle Schøyen, MD, PhDPrincipal Investigator

Sites

3 total
Bergen, NorwayStavanger, NorwayTrondheim, Norway

Linked catalysts

1
The Norwegian Prednisolone in Early Psychosis Study — primary completion2021-12-31

Facts & assertions

4 sourced
Enrollment
12
Phase
PHASE2
Primary Completion Date
2021-12-31
Status
TERMINATED
relationships
The graph out of here
drug
Prednisolone
drug
lead_sponsor
Haukeland University Hospital
company
collaborator
Helse Stavanger HF
company
St. Olavs Hospital
company
indication
Psychosis
indication
Psychotic Disorders
indication
Schizophrenia and Related Disorders
indication
investigator
Erik Johnsen, MD, PhD
person
Solveig Klæbo Reitan, MD, PhD
person
Helle Schøyen, MD, PhD
person